We are the Pannexin company

David, is the founder of Pannex Therapeutics and has worked, in the area of Pannexin 1 and chronic pain as a target, for many years. He is a successful serial entrepreneur, expert in industrial development, guiding his previous and current companies to transform scientific research into viable products. He successfully raised public funds and private investments for his current and past companies. With 10 years of experience in R&D and management of innovative technological projects in Neuroscience and Neuropharmacology, David has the experience and drive to build a successful company and to transform his initial research on Pannexin 1 and pain into a commercially successful product. David holds a PhD in Neuroscience from the University of Santiago, Chile, was awarded with the National Prize of Innovation in Chile in 2015.

Thomas brings more than 30 years of experience in biopharmaceuticals and venture capital, in a broad range of areas. He has worked in big multinational companies like Knoll and Novartis in Germany and Switzerland, but also in successful startups like Actelion, (Switzerland and Brazil), early startup like Biozeus (Brazil) and in venture capital, focused on biopharmaceuticals, diagnostics and medical equipment. During his career, he worked in drug development, leading global teams, but also in commercial and operational functions, as general manager of Actelion Brazil. During his 9 years in venture capital he identified investment opportunities and supported portfolio companies on operational as well as board level. Thomas holds an PhD in Biology and an BA in chemistry, from the university of Mainz (Germany) and has spent 3 years as researcher at Michigan State University.

Gerhard has more than 30 years of experience in drug development, holding senior positions in global pharmaceutical companies in several countries. His specific focus is drug discovery (ADME/PK), screening and profiling lead candidates, and general drug development. He was a key player in the development and registration of numerous drugs during his time at Aventis, Novartis and Lundbeck e.g. Leflunomide, Gliveec, Myfortic, Zoledronate, Zelmac, Everolimus, Pimecrolimus, ERL080, Exjade, Aliskirenn and holds many patents. During his time at Janssen he set up a new strategy for the department of drug developability and introducing the concept of receptor binding kinetics for PK/PD and establishing global in silico ADMET approaches for discovery. Gerhard has a M.Sc. in Physics and Chemistry, a Ph.D. in Organic Chemistry from the University of Marburg, Germany and a postdoc at the university of Utah, USA.